Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Feb;96(2):363–371. doi: 10.1111/j.1476-5381.1989.tb11826.x

Pharmacological modulation of Paf-induced rat pleurisy and its role in inflammation by zymosan.

M A Martins 1, P M Silva 1, H C Faria Neto 1, P T Bozza 1, P M Dias 1, M C Lima 1, R S Cordeiro 1, B B Vargaftig 1
PMCID: PMC1854341  PMID: 2924083

Abstract

1. The intrapleural injection of Paf-acether into rats caused, at 30 min, a marked exudation accompanied by a reduction in the pleural leucocyte count. At 6 h, the exudate volume had decreased and a significant increase in the total leucocyte count, particularly eosinophils was noted. 2. Two Paf-acether antagonists, WEB 2086 and 48740 RP abrogated the pleural leucopenia observed 30 min after Paf-acether administration, whereas the exudation was inhibited only by the former. Pleurisy was also reduced by about 60% with dexamethasone, by about 45% with BW 755C or LY 171883, a mixed cyclo-oxygenase/lipoxygenase inhibitor and a peptido-leukotriene antagonist respectively, and by about 30% with indomethacin, flurbiprofen or piroxicam. 3. Repeated daily intrapleural injections of Paf-acether led to a state of progressive desensitization to Paf-acether itself, whereas responsiveness to 5-hydroxytryptamine was maintained. In addition, the Paf-induced auto-desensitization was largely inhibited by WEB 2086. 4. Pleurisy induced by zymosan, but not by carrageenin, was significantly reduced in Paf-acether-desensitized animals. These results were consistent with those obtained with WEB 2086 which suppressed zymosan-induced but not carrageenin-induced pleurisy. 5. This study suggests that Paf-acether-induced pleurisy in the rat may be mediated by lipoxygenase arachidonic acid metabolites and that pleurisy induced by zymosan, but not by carrageenin, is largely dependent upon Paf-acether.

Full text

PDF
363

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björk J., Smedegård G. Acute microvascular effects of PAF-acether, as studied by intravital microscopy. Eur J Pharmacol. 1983 Dec 9;96(1-2):87–94. doi: 10.1016/0014-2999(83)90532-0. [DOI] [PubMed] [Google Scholar]
  2. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  3. Bureau M., Joseph D., Vargaftig B. B. Desensitization and antagonism of rat polymorphonuclear leukocytes stimulated with PAF acether. Prostaglandins. 1987 Jan;33(1):37–50. doi: 10.1016/0090-6980(87)90303-0. [DOI] [PubMed] [Google Scholar]
  4. Bussolino F., Camussi G., Aglietta M., Braquet P., Bosia A., Pescarmona G., Sanavio F., D'Urso N., Marchisio P. C. Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol. 1987 Oct 1;139(7):2439–2446. [PubMed] [Google Scholar]
  5. Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987 Jun;241(3):974–981. [PubMed] [Google Scholar]
  6. Colditz I. G., Movat H. Z. Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. J Immunol. 1984 Oct;133(4):2169–2173. [PubMed] [Google Scholar]
  7. Cordeiro R. S., Martins M. A., Silva P. M., Faria Neto H. C., Castanheira J. R., Vargaftig B. B. Desensitization to PAF-induced rat paw oedema by repeated intraplantar injections. Life Sci. 1986 Nov 17;39(20):1871–1878. doi: 10.1016/0024-3205(86)90297-3. [DOI] [PubMed] [Google Scholar]
  8. Demopoulos C. A., Pinckard R. N., Hanahan D. J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 Oct 10;254(19):9355–9358. [PubMed] [Google Scholar]
  9. Detsouli A., Lefort J., Vargaftig B. B. Histamine and leukotriene-independent guinea-pig anaphylactic shock unaccounted for by Paf-acether. Br J Pharmacol. 1985 Apr;84(4):801–810. doi: 10.1111/j.1476-5381.1985.tb17374.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Findlay S. R., Lichtenstein L. M., Hanahan D. J., Pinckard R. N. Contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. Am J Physiol. 1981 Sep;241(3):C130–C133. doi: 10.1152/ajpcell.1981.241.3.C130. [DOI] [PubMed] [Google Scholar]
  11. Fleisch J. H., Rinkema L. E., Haisch K. D., Swanson-Bean D., Goodson T., Ho P. P., Marshall W. S. LY171883, 1-less than 2-hydroxy-3-propyl-4-less than 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist. J Pharmacol Exp Ther. 1985 Apr;233(1):148–157. [PubMed] [Google Scholar]
  12. Halonen M., Palmer J. D., Lohman I. C., McManus L. M., Pinckard R. N. Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. Am Rev Respir Dis. 1980 Dec;122(6):915–924. doi: 10.1164/arrd.1980.122.6.915. [DOI] [PubMed] [Google Scholar]
  13. Handley D. A., Arbeeny C. M., Lee M. L., Van Valen R. G., Saunders R. N. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology. 1984 Dec;8(3-4):137–142. doi: 10.1016/0162-3109(84)90017-1. [DOI] [PubMed] [Google Scholar]
  14. Henocq E., Vargaftig B. B. Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man. Lancet. 1986 Jun 14;1(8494):1378–1379. doi: 10.1016/s0140-6736(86)91683-1. [DOI] [PubMed] [Google Scholar]
  15. Henson P. M. Platelet-activating factor (PAF) as a mediator of neutrophil-platelet interactions in inflammation. Agents Actions. 1981 Dec;11(6-7):545–547. doi: 10.1007/BF01978732. [DOI] [PubMed] [Google Scholar]
  16. Humphrey D. M., McManus L. M., Satouchi K., Hanahan D. J., Pinckard R. N. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab Invest. 1982 Apr;46(4):422–427. [PubMed] [Google Scholar]
  17. Hwang S. B., Lam M. H., Li C. L., Shen T. Y. Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema. Eur J Pharmacol. 1986 Jan 14;120(1):33–41. doi: 10.1016/0014-2999(86)90636-9. [DOI] [PubMed] [Google Scholar]
  18. Hwang S. B., Li C. L., Lam M. H., Shen T. Y. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. Lab Invest. 1985 Jun;52(6):617–630. [PubMed] [Google Scholar]
  19. Håkansson L., Westerlund D., Venge P. New method for the measurement of eosinophil migration. J Leukoc Biol. 1987 Dec;42(6):689–696. doi: 10.1002/jlb.42.6.689. [DOI] [PubMed] [Google Scholar]
  20. Jancar S., Braquet P., Sirois P. Interactions of arachidonic acid metabolites and platelet activating factor and mechanism of action in hypersensitivity reactions. Braz J Med Biol Res. 1987;20(5):487–494. [PubMed] [Google Scholar]
  21. Keraly C. L., Benveniste J. Specific desensitization of rabbit platelets by platelet-activating factor (PAF-acether) and derivatives. Br J Haematol. 1982 Jun;51(2):313–322. [PubMed] [Google Scholar]
  22. Lefort J., Sedivy P., Desquand S., Randon J., Coëffier E., Maridonneau-Parini I., Floch A., Benveniste J., Vargaftig B. B. Pharmacological profile of 48740 R.P., a PAF-acether antagonist. Eur J Pharmacol. 1988 Jun 10;150(3):257–268. doi: 10.1016/0014-2999(88)90006-4. [DOI] [PubMed] [Google Scholar]
  23. Lefort J., Vargaftig B. B. Role of platelets in aspirin-sensitive bronchoconstriction in the guinea-pig; interactions with salicylic acid. Br J Pharmacol. 1978 May;63(1):35–42. doi: 10.1111/j.1476-5381.1978.tb07771.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lellouch-Tubiana A., Lefort J., Simon M. T., Pfister A., Vargaftig B. B. Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Modulation by prostacyclin, platelet depletion, and selective antagonists. Am Rev Respir Dis. 1988 Apr;137(4):948–954. doi: 10.1164/ajrccm/137.4.948. [DOI] [PubMed] [Google Scholar]
  25. Maridonneau-Parini I., Lagente V., Lefort J., Randon J., Russo-Marie F., Vargaftig B. B. Desensitization to PAF-induced bronchoconstriction and to activation of alveolar macrophages by repeated inhalations of PAF in the guinea pig. Biochem Biophys Res Commun. 1985 Aug 30;131(1):42–49. doi: 10.1016/0006-291x(85)91767-x. [DOI] [PubMed] [Google Scholar]
  26. Martins M. A., Silva P. M., Castro H. C., Neto F., Lima M. C., Cordeiro R. S., Vargaftig B. B. Interactions between local inflammatory and systemic haematological effects of PAF-acether in the rat. Eur J Pharmacol. 1987 Apr 29;136(3):353–360. doi: 10.1016/0014-2999(87)90308-6. [DOI] [PubMed] [Google Scholar]
  27. Mencia-Huerta J. M., Benveniste J. Platelet-activating factor (PAF-acether) and macrophages. II. Phagocytosis-associated release of PAF-acether from rat peritoneal macrophages. Cell Immunol. 1981 Jan 15;57(2):281–292. doi: 10.1016/0008-8749(81)90087-3. [DOI] [PubMed] [Google Scholar]
  28. Pirotzky E., Page C. P., Roubin R., Pfister A., Paul W., Bonnet J., Benveniste J. PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils. Microcirc Endothelium Lymphatics. 1984 Feb;1(1):107–122. [PubMed] [Google Scholar]
  29. Pirotzky E., Pfister A., Benveniste J. A role for Paf-acether (platelet-activating factor) in acute skin inflammation? Br J Dermatol. 1985 Jul;113 (Suppl 28):91–94. doi: 10.1111/j.1365-2133.1985.tb15632.x. [DOI] [PubMed] [Google Scholar]
  30. Shaw J. O., Pinckard R. N., Ferrigni K. S., McManus L. M., Hanahan D. J. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor). J Immunol. 1981 Sep;127(3):1250–1255. [PubMed] [Google Scholar]
  31. Silva P. M., Cordeiro R. S., Martins M. A., Henriques M. G., Vargaftig B. B. Platelet involvement in rat paw edema induced by 2-methoxy-PAF. Inflammation. 1986 Dec;10(4):393–401. doi: 10.1007/BF00915823. [DOI] [PubMed] [Google Scholar]
  32. Smith R. J., Bowman B. J., Iden S. S. Stimulation of the human neutrophil superoxide anion-generating system with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3- phosphorylcholine. Biochem Pharmacol. 1984 Apr 1;33(7):973–978. doi: 10.1016/0006-2952(84)90502-1. [DOI] [PubMed] [Google Scholar]
  33. Tarayre J. P., Delhon A., Bruniquel F., Puech L., Tisne-Versailles J., Couzinier J. P. Exudative, cellular and humoral reactions to platelet-activating factor (PAF-acether) in the pleural cavity of rats. Eur J Pharmacol. 1986 May 27;124(3):317–323. doi: 10.1016/0014-2999(86)90233-5. [DOI] [PubMed] [Google Scholar]
  34. Tokumura A., Harada K., Fukuzawa K., Tsukatani H. Biphasic action of platelet-activating factor on isolated guinea-pig ileum. Lipids. 1983 Nov;18(11):848–850. doi: 10.1007/BF02534647. [DOI] [PubMed] [Google Scholar]
  35. Vargaftig B. B., Ferreira S. H. Blockade of the inflammatory effects of platelet-activating factor by cyclo-oxygenase inhibitors. Braz J Med Biol Res. 1981 Jul;14(2-3):187–189. [PubMed] [Google Scholar]
  36. Voelkel N. F., Worthen S., Reeves J. T., Henson P. M., Murphy R. C. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science. 1982 Oct 15;218(4569):286–289. doi: 10.1126/science.7123233. [DOI] [PubMed] [Google Scholar]
  37. Wardlaw A. J., Moqbel R., Cromwell O., Kay A. B. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest. 1986 Dec;78(6):1701–1706. doi: 10.1172/JCI112765. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES